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OBJECTIVE—Glucagon-like peptide-1 (GLP-1) promotes glu-
cose homeostasis through regulation of islet hormone secretion,
as well as hepatic and gastric function. Because GLP-1 is also
synthesized in the brain, where it regulates food intake, we
hypothesized that the central GLP-1 system regulates glucose
tolerance as well.
RESEARCH DESIGN AND METHODS—We used glucose
tolerance tests and hyperinsulinemic-euglycemic clamps to as-
sess the role of the central GLP-1 system on glucose tolerance,
insulin secretion, and hepatic and peripheral insulin sensitivity.
Finally, in situ hybridization was used to examine colocalization
of GLP-1 receptors with neuropeptide tyrosine and pro-opiomela-
nocortin neurons.
RESULTS—We found that central, but not peripheral, adminis-
tration of low doses of a GLP-1 receptor antagonist caused
relative hyperglycemia during a glucose tolerance test, suggest-
ing that activation of central GLP-1 receptors regulates key
processes involved in the maintenance of glucose homeostasis.
Central administration of GLP-1 augmented glucose-stimulated
insulin secretion, and direct administration of GLP-1 into the
arcuate, but not the paraventricular, nucleus of the hypothala-
mus reduced hepatic glucose production. Consistent with a role
for GLP-1 receptors in the arcuate, GLP-1 receptor mRNA was
found to be expressed in 68.1% of arcuate neurons that expressed
pro-opiomelanocortin mRNA but was not signiﬁcantly coex-
pressed with neuropeptide tyrosine.
CONCLUSIONS—These data suggest that the arcuate GLP-1
receptors are a key component of the GLP-1 system for improv-
ing glucose homeostasis by regulating both insulin secretion and
glucose production. Diabetes 57:2046–2054, 2008
T
he importance of gastrointestinal hormones sig-
naling gut absorption of carbohydrates and
downstream processes involved in glucose dis-
posal has received increasing attention. Promi-
nent among these is glucagon-like peptide-1 (GLP-1),
which is produced by L-cells of the ileum and is secreted
during meal ingestion. GLP-1 augments nutrient-induced
insulin release (1,2), inhibits glucagon release (3), slows
gastric emptying (4), and has islet-independent effects
to reduce hepatic glucose production (5–8). Studies in
animals and humans have demonstrated that GLP-1
signaling is necessary for normal glucose tolerance (9).
Moreover, two newly approved therapies for type 2
diabetic patients act through GLP-1 signaling to improve
glucose homeostasis.
Most of the evidence demonstrating a role for GLP-1 in
glucose homeostasis has focused on actions within the
pancreatic islet. However, GLP-1 is also synthesized in a
discrete population of neurons in the hindbrain (10–12),
and GLP-1 receptors are highly expressed in various
regions of the hypothalamus (13) including the arcuate
nucleus (ARC) and the paraventricular nucleus (PVN)
(14), two areas where immunoreactive GLP-1 ﬁbers termi-
nate (11). Central nervous system (CNS) GLP-1 receptors
have been linked to the control of food intake, endocrine
and behavioral responses to stress, and visceral illness
(15–17). Although there is evidence that circulating GLP-1
agonists can activate CNS neurons (18) and that GLP-1
may cross the blood-brain barrier (19), central and periph-
eral GLP-1 signaling systems are generally held to be
separate.
Compelling recent evidence links a number of CNS
systems to the regulation of peripheral glucose levels.
While hypothalamic areas such as the PVN and the dorsal
medial and the ventromedial hypothalamus may play a
role in glucose homeostasis during stress (20–22), there is
strong evidence that the ARC plays a key role in maintain-
ing normal glucose levels in response to anorectic pep-
tides or nutrients by regulation of glucose production
(23–26). Given this emerging evidence for CNS involve-
ment in the regulation of peripheral metabolism and the
broad role that peripheral GLP-1 signaling plays in regu-
lating glucose homeostasis, we hypothesized that CNS
GLP-1 receptors would have multiple coordinated effects
to improve glucose tolerance. Speciﬁcally, we focused on
the ARC because GLP-1 receptors are found in this region,
and previous studies have shown that neurons in this area
regulate glucose production. Thus, a second hypothesis
was that ARC GLP-1 receptors regulate glucose output.
Finally, using dual in situ hybridization histochemistry, we
evaluated ARC GLP-1 receptor expression on orexigenic
neuropeptide tyrosine (NPY) and anorexigenic proopio-
melanocortin (POMC) neurons.
RESEARCH DESIGN AND METHODS
Male Long-Evans rats (300–350 g) from Harlan (Indianapolis, IN) were housed
in the University of Cincinnati Laboratory Animals for Medical Science
Facility at the Genome Research Institute under controlled conditions (12:12
light-dark cycle, 50–60% humidity, and 25°C) with free access to rodent food
and water. All procedures for animal use were approved by the University of
Cincinnati Institutional Animal Care and Use Committee.
One week before the study, under anesthesia (isoﬂourine), rats had
catheters placed in the carotid artery and jugular vein. For some studies, a
stainless steel cannula was placed in the third cerebral ventricle (i3vt) (22
gauge, 11 mm, and i3vt; coordinates: 2.2 A/P and 7.5 D/V), the ARC (26 ga and
11 mm; coordinates: 1.8 mol/l/l; 3.0 A/P and 8.6 D/V, at 10°) or the PVN (26 ga
and 11 mm; coordinates: 0.2 mol/l/l; 2.2 A/P and 7.5 D/V) of the brain using
stereotaxic (ASI Instruments, Warren, MI) coordinates as determined by the
atlas of Paxinos and Watson (27). Rats were studied after regaining at least
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2046 DIABETES, VOL. 57, AUGUST 200890% of presurgery body weight (1 week). An additional set of animals had
cannulas placed in the ARC or PVN, as described above, but without catheters.
The i3vt cannula placement was veriﬁed in rats drinking 5 ml water 1 h after
CNS injection of angiotensin II. Postmortem cannula placement for rats
implanted with the ARC or PVN cannulas was veriﬁed after toluidine blue
injection into the cannula. The brains were removed, fresh frozen, and
subsequently cut with a cryostat set at 30 m. The dye was then visualized on
brain slices using a microscope. Only rats with correct placement of cannulas
(Fig. 5) were included in the ﬁnal analyses.
Intraperitoneal glucose tolerance tests. Eight overnight-fasted rats re-
ceived a i3vt injection (50 g; 2 l/15 s) of a potent GLP-1 receptor antagonist,
des-His1,Glu8-exendin-4 (dH-EX) (n  4 [28,29]) or saline (n  4). Five
minutes later, an intraperitoneal injection of 50% dextrose (2 g/kg) was given.
Blood samples were taken from the tail at baseline and at 15, 30, 45, 60, and
120 min and at 0, 15, 30 and 60 min after the intraperitoneal injection for
glucose and insulin assessment, respectively.
Intravenous glucose tolerance tests. Overnight-fasted rats received an i3vt
injection of GLP-1 (3 gi n2l/15 s; n  8) or saline (n  7), followed 5 min
later by an intravenous bolus of 20% dextrose (0.5 mg/kg). Blood samples for
glucose and insulin were taken at baseline (10 and 6 min) and every 2 min
from 2 through 10 min and then at 20 and 30 min after the intravenous
glucose infusion.
Hyperinsulinemic-euglycemic clamp experiments. Overnight-fasted rats
were conscious and unrestrained during the experimental period. The morn-
ing of the study, rats were weighed and the exteriorized catheters were
extended for ease of access. To measure glucose kinetics, a primed (30 Ci)
constant (0.3 Ci/min) infusion of high-performance liquid chromatography–
puriﬁed [3-
3H]glucose (Perkin Elmer Life Sciences, Boston, MA) was admin-
istered via a precalibrated infusion pump (Harvard Apparatus, South Natick,
MA) at 0–270 min. At 120–270 min, GLP-1 was infused into either the i3vt
(n  7), the ARC (n  7), or the PVN (n  7) at 0.01 g/min, or saline was
infused into either the ARC (n  7) or PVN (n  7) at 0.1 l/min. In another
group of animals, GLP-1 plus glibenclamide (200 pmol total intra-ARC dose
[25]), an ATP-sensitive K
 channel (KATP channel) blocker, was coinfused into
the ARC to determine the role of these channels in GLP-1–induced changes in
glucose kinetics. From 150 to 270 min, a primed (30 pmol  kg
1  min
1),
continuous (15 pmol  kg
1  min
1) infusion of insulin (Eli Lilly, Indianapolis,
IN) was administered via a precalibrated infusion pump (Harvard Apparatus,
South Natick, MA). This insulin infusion rate was used because our prelimi-
nary data showed that it did not completely suppress glucose production,
allowing the determination of an effect of CNS GLP-1 on both glucose
production and glucose uptake. A variable rate 50% dextrose infusion main-
tained blood glucose at 5.6 mmol/l. During the clamp, the [3-
3H]glucose
infusion rate was increased to 0.6 Ci/min to maintain constant speciﬁc
activity. During the experimental period, blood was drawn every 5–15 min for
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FIG. 1. Effect of blocking CNS GLP-1 receptors on glucose (A) and
insulin (B) responses to an intraperitoneal glucose injection. A: Glu-
cose response to the intraperitoneal glucose load was signiﬁcantly
greater at 15 and 30 min after the glucose injection with dH-EX versus
saline injected into the i3vt. Integrated area under the curve (iAUC)
was also signiﬁcantly greater in dH-EX versus saline (inlay). B: There
were no signiﬁcant differences between groups in the insulin response
to the glucose load. *P 0.05 vs. saline.
TABLE 2
Blood glucose levels during an intraperitoneal glucose tolerance
test (IPGTT) with intraperitoneally administered dH-EX or sa-
line, after an IVGTT with i3vt GLP-1 or saline, and after intra-
venously administered saline plus i3vt GLP-1 or saline
GLP-1 Saline dH-EX
IPGTT (min)
08 7  39 0  4
15 303  22 269  28
30 281  19 248  17
45 253  16 211  17
60 228  16 185  13
IVGTT (min)
09 4  49 6  4
2 279  20 245  29
4 241  10 224  17
10 169  16 161  17
20 122  13 115  10
Intravenous saline (min)
09 4  79 2  4
28 9  89 5  4
49 4  79 3  6
10 97  10 91  6
20 107  12 91  7
There were no statistical differences in glucose levels between
intraperitoneal dH-EX and saline during the intraperitoneal glucose
tolerance test or between i3vt GLP-1 versus saline with either
intravenous glucose or saline.
TABLE 1
Percentage of double-labeled POMC and GLP-1 receptor neurons
expressed in rat retrochiasmatic nucleus (RCh) and different
areas of the ARC
Percent POMC
neurons expressing
GLP-1 receptor
Percent GLP-1
receptor neurons
expressing POMC
RCh 40.0  10.7 34.8  14.9
Rostral ARC 61.8  4.5 50.6  3.2
Mid-ARC 68.5  4.3 45.1  3.5
Caudal ARC 71.8  3.7 35.8  1.9
Total ARC 68.1  2.4 43.1  2.1
Data are means  SE. Ten sections per animals were used, and both
sides of the retrochiasmatic nucleus and ARC for three animals were
analyzed to generate these data.
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every 15 min during the experimental periods for [3-
3H]glucose and at times
120, 150, and 270 min for plasma insulin levels.
Tracer calculations. Rates of glucose appearance (Ra), glucose production,
and glucose utilization were calculated according to previous methods
(30,31). Brieﬂy, endogenous glucose production was calculated by determin-
ing the total Ra (this comprises both glucose production and any exogenous
glucose infused to maintain the desired glycemic levels) and subtracting it
from the amount of exogenous glucose infused.
Anatomical localization of ARC GLP-1 receptor–expressing cells.
Brains from male Long-Evans and Sprague-Dawley rats (250–300 g) were
frozen and sectioned (12 m) on a cryostat. The following plasmids were used
for probe synthesis: 1) for GLP-1 receptors, the full-length rat sequence
including 83 bp of the 3 untranslated region was inserted into pBSII KS
(Stratagene, San Diego, CA); 2) for POMC, a 900-bp fragment was inserted into
pGEM4z (Promega, Madison WI); and 3) for NPY, a full-length fragment was
inserted into pBSSK (Stratagene). For generating antisense cRNAs, GLP-1
receptors and NPY plamids were linearized with HindIII, and T7 polymerase
was used for in vitro transcription. POMC plasmid was linearized with EcoRI,
and T3 polymerase was used for in vitro transcription to generate antisense
cRNA. Sense and antisense
33P-radiolabeled (GLP-1 receptors) or digoxigenin-
labeled (POMC and NPY) cRNAs were generated using standard manufacturer
protocols and added to a ﬁnal concentration of 16  10
6 cpm and 800–1,600
ng/slide, respectively. Double in situ hybridization histochemistry was per-
formed according to previously published protocols (21,32).
Three-dimensional serial section reconstruction and neuron mapping.
Microscopic examinations were made on an Olympys BX51 connected to a
digital camera CX9000 (MBF Biosciences) controlled by Stereoinvestigator
software (version 7.51.1; MBF Biosciences). Pictures were acquired under
10 and 40 objectives, and anatomical maps were generated using the 40
objective under simultaneous brightﬁeld and lateral darkﬁeld illumination
using a Darklite illuminator (Micro Video Instruments, Avon, MA).
Ten sections spanning the retrochiasmatic nucleus and the ARC were used
to generate quantitative data as well as three-dimensional anatomical recon-
structions from three rats. Both sides of the ARC were analyzed. Each section
was separated by 240 m. Anatomical maps were generated for each rat using
Stereoinvestigator. Each section was acquired using the serial section module
aligned to previous sections, and colored symbols were used to represent
neurons. Single- and double-labeled neurons for POMC and GLP-1 receptors
were traced for each section. Cells were counted as positive for GLP-1
receptor mRNA when the number of silver grain accumulated over the cell
body was at least 5 above the background (area devoid of cells, e.g., the
corpus callosum). For digoxigenin staining, cells were counted only if they
displayed a clear cellular morphology and their size was within the range of
average size of cell bodies within this area. When a cluster of cells was
encountered, only cells with a clearly visualized nucleus were scored.
Double-labeled cells were scored when the silver-grain accumulation conﬁned
to the digoxigenin labeling was at least 5 above background. Three-
dimensional model graphics were generated using the solid-modeling module
and rotated using Neurolucida Explorer (version 4.50.4; MBF Biosciences).
Food intake. Food was removed 3 h before dark onset. Immediately before
dark onset, rats with cannulas directed at the ARC (unilateral, n  35;
bilateral, n  18) or PVN (n  11) were injected with 0.3 g  0.1 l
1  1
1 
min
1 GLP-1 or 0.1 l/1 min saline using a precalibrated infusion pump
(Harvard Apparatus, South Natick, MA). This dose of GLP-1 was chosen
because it is less than the lowest effective dose found with i3vt administration
of GLP-1 (3 g [17]) and similar to previous site-speciﬁc doses of GLP-1 (33).
Food was weighed at baseline and 0.5, 1, and 2 h after dark onset.
Analytical methods. Blood glucose was measured using a Freestyle (Thera-
sense, Almeda, CA) glucose analyzer. Insulin and glucagon were measured
using radioimmunoassay techniques with a standard antiserum method for
insulin (34) and a commercial kit for glucagon (Linco, St. Louis, MO). Plasma
[
3H]glucose radioactivity was measured using the Somogyi procedure, as
previously described (31).
i3vt 
Injection
IV 
Injection 
*
0
100
200
I
n
s
u
l
i
n
 
(
p
M
)
-6 -2 2 4 6 8 10 20 30
Time (min)
0
10000
20000
(
p
M
)
*
m
i
n
SAL GLP-1
Insulin iAUC
0
500
1000
1500
I
n
s
u
l
i
n
 
(
p
M
) Saline
GLP-1 *
A
B
FIG. 2. Insulin response to an intravenous glucose or saline bolus 5 min
after i3vt GLP-1 or saline injection. A: Insulin levels were signiﬁcantly
greater at 4 min, and area under the curve for insulin response was
signiﬁcantly greater after GLP-1 (inset). B: Insulin levels did not
signiﬁcantly change with an intravenous saline bolus after i3vt GLP-1
and saline injections. *P < 0.05 vs. saline.
FIG. 3. Photomicrographs illustrating the expression of GLP-1r mRNAs
in NPY and POMC neurons in rat mid- and caudal ARC as detected by
double in situ hybridization histochemistry. Neurons expressing GLP-1
receptor are visualized by a white, dense, silver-grain accumulation,
while either NPY (A–C) or POMC (D–F) mRNAs appeared as a black
precipitate in cell bodies. In the mid-ARC at low magniﬁcation (A and
D), many GLP-1 receptor–expressing cells do not express NPY mRNA
and are localized more laterally (A). Neurons expressing only GLP-1r
are also visualized in the periventricular area posterior to both NPY
and POMC neurons (A and D). A high number of POMC-expressing
cells are found expressing GLP-1r mRNA characterized by strong
silver-grain accumulation over the digoxigenin black precipitate and
are clearly seen at higher magniﬁcation (F). In the caudal ARC (B and
E), many neurons expressing the GLP-1 receptor but not NPY or POMC
are found mostly in the posterior and periventricular part (B and E). C
and F are photomicrographs at higher magniﬁcation of inserts repre-
sented by a black square in A and D.
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tests and mixed-model ANOVAs where appropriate. Post hoc tests of individ-
ual groups were made using Tukey’s post hoc tests. Statistical signiﬁcance
was set at P 	 0.05 for all analyses.
RESULTS
Effect of CNS GLP-1 receptors on glucose homeostasis.
Rats injected with dH-EX in the i3vt were hyperglycemic
for the ﬁrst 45 min after the intraperitoneal glucose load
compared with the saline-injected rats (Fig. 1A) and had a
50% increase in the glycemic response to intraperitoneal
glucose, as represented by the area under the curve above
baseline (P 	 0.05). Despite these marked differences in
plasma glucose during the intraperitoneal glucose toler-
ance test, there were no differences in insulin levels
between the groups (Fig. 1B). The same dose of dH-EX
that disrupted glucose homeostasis when given in the CNS
had no effect when given peripherally (Table 1), and in a
separate group of animals, we found that 20 min after an
intraperitoneal glucose load, plasma GLP-1 levels did not
signiﬁcantly increase over baseline (n  4; mean  SE
43  20 vs. 54  36 pmol/l).
CNS GLP-1 and insulin secretion. To test whether the
comparable plasma insulin concentrations during an intra-
peritoneal glucose load in dH-EX– and saline-treated rats
in the presence of substantially different levels of glucose
were due to CNS GLP-1 regulation of the 
-cell, we
administered GLP-1 into the i3vt before an intravenous
glucose tolerance test (IVGTT). We found that despite
similar glucose levels (Table 1), i3vt GLP-1 versus saline
signiﬁcantly increased insulin levels and insulin area under
the curve (AUC) during the IVGTT (Fig. 2A), whereas
when the same dose of GLP-1 was combined with intra-
venous saline, there was no signiﬁcant effect on blood
glucose (Table 1) or insulin levels (Fig. 2B). We used an
IVGTT because in response to a single bolus of intrave-
nous glucose, plasma glycemia in the ﬁrst 10 min is
primarily a function of body compartment distribution
rather than insulin action, and the rapid return to baseline
(within 20 min) allowed us to isolate the effects of CNS
GLP-1 on insulin secretion independently without the
potential confounding inﬂuence of insulin-mediated glu-
cose disposal. Furthermore, the fact that insulin levels
increase over 10-fold more than baseline and return to
baseline within 20 min suggests that a change in insulin
clearance is an unlikely explanation for the increased
insulin levels.
Expression of ARC GLP-1 receptor mRNA in NPY and
POMC neurons. As previously shown (14), we found
numerous cells expressing GLP-1 receptors in the ARC
(Fig. 3). Many of the GLP-1 receptor–containing cells also
appeared to coexpress POMC mRNA. However, there was
virtually no colocalization of GLP-1 receptor with NPY
neurons, which were generally more medial and ventral
compared with GLP-1 receptor mRNAs containing cells
(Fig. 3A–C).
In the retrochiasmatic nucleus, an average of 40.0 
10.7% of the POMC neurons also coexpressed GLP-1
receptor mRNA, whereas in the ARC, an average of 68.1 
FIG. 4. Illustrations of computer-assisted anatomical mapping and three-dimensional serial section reconstruction of POMC, GLP-1 receptors,
and POMC/GLP-1 receptor–expressing cells in rat retrochiasmatic and arcuate nuclei. Anatomical maps were generated by drawing colored
symbols over each cell type during examination of microscopic slides under a 40 objective. Green dots or squares, cells expressing GLP-1
receptor alone. Blue dots or triangles, cells expressing POMC alone. Red dots, cells expressing both GLP-1 receptor and POMC. 3v, third ventricle;
PVH, paraventricular nucleus of the hypothalamus. (Please see http://dx.doi.org/10.2337/db07-1824 for a high-quality digital representation of
this ﬁgure.)
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part of the nucleus expressed GLP-1 receptor as well
(Table 2 and Fig. 3D–F). Overall, about half of the GLP-1
receptor–expressing cells did not express either NPY or
POMC mRNA. These neurons were located mostly in the
dorsal part of the ARC around the i3vt and, to a lesser
extent, at the lateral edge of the nucleus (Figs. 3 and 4).
These cells also seem to be more abundant in the caudal
part of the ARC (Fig. 4).
The graphical three-dimensional representation of the
ARC allowed us to clearly identify two distinct populations
of POMC neurons. One population, found predominantly
in the medio-lateral part of the ARC, coexpressed GLP-1
receptor mRNA. The other population was found at the
lateral edge of the nucleus and largely did not coexpress
GLP-1 receptors (Fig. 4A, B, and D). Note the abundance
of GLP-1 receptor–expressing cells (green dots) in the
periventricular and lateral edge of the ARC (Fig. 4A, C, and
D). GLP-1 receptor–expressing cells are also more numer-
ous in the caudal ARC (large arrows in Fig. 4B and D),
speciﬁcally in its medial posterior part. While the in vivo
experiments were performed in Long-Evans rats and the
anatomical data were performed on brains of Sprague-
Dawley rats, we have found similar patterns of distribution
in GLP-1 receptors between the two strains (data not
shown).
CNS GLP-1 and hyperinsulinemic-euglycemic clamps.
Basal insulin and corticosterone (Table 3) levels were
similar among groups and did not change with intracere-
broventricular infusions. Based on relatively unchanging
plasma glucose concentrations and glucose speciﬁc activ-
ity (coefﬁcients of variation 5.4  0.6 and 5.7  0.8% for
basal and ﬁnal 30 min, respectively), basal glucose produc-
tion and glucose uptake were not signiﬁcantly affected by
CNS GLP-1 (37  4, 42  6, and 41  4 mol  kg
1  min
1
for saline, ARC, and i3vt GLP-1, respectively).
Glucose and insulin levels were well matched among
the groups during the clamps (Table 3). Insulin levels
were comparable with those measured during the intra-
peritoneal glucose tolerance test (Fig. 1B), indicating
that the levels of insulin were within physiological
range. Basal glucose kinetics were similar among the
groups (Table 4). During the clamp, the amount of
glucose infused to maintain glycemic levels did not
differ among the saline-, ARC-, and i3vt GLP-1–treated
rats, indicative of similar rates of whole-body insulin
sensitivity (Fig. 6A). However, ARC GLP-1 signiﬁcantly
inhibited glucose production (Fig. 6B) and glucose
uptake (Fig. 6C) by the end of the clamp period. While
the glucose production rates between saline and i3vt
GLP-1 groups did not differ, the same low dose of GLP-1
infused into the i3vt as that infused into the ARC also
inhibited glucose uptake. However, the same rate and
concentration of GLP-1 (vs. saline) infused into the PVN
did not alter glucose production or glucose uptake (Fig.
7A–C). Thus, these data indicate that increased GLP-1
signaling, speciﬁcally in the ARC, can produce signiﬁ-
cant changes in both glucose production and uptake.
While the effects of central GLP-1 to lower glucose
production appear to be speciﬁc for the ARC, the
comparable reduction in glucose uptake with i3vt and
ARC GLP-1 raises the possibility that other brain areas
could mediate this process.
We infused glibenclamide, at a dose that has previously
been shown to block insulin- and nutrient-induced de-
creases in glucose production (24,25), together with GLP-1
into the ARC during the hyperinsulinemic-euglycemic
clamp. Glibenclamide had no effect on basal glucose and
insulin levels, basal glucose kinetics (data not shown), or
glucose infusion rate during the clamp (Fig. 6D) but,
consistent with previous data, did block both effects of
ARC GLP-1 on glucose production and glucose uptake
(Fig. 6E and F).
FIG. 5. ARC and PVN cannula-placement sites. After completion of the
hyperinsulinemic-euglycemic clamps, the animals were killed and tolu-
dine blue dye was injected into the cannula. The brain was then
sectioned and placement was veriﬁed. Black dots represent correct
cannula placement. Rats with cannulas not placed in the ARC and PVN
were excluded from the analysis (n  8).
TABLE 3
Plasma glucose, insulin, and corticosterone levels prior to and
during the hyperinsulinemic-euglycemic clamp
ARC
saline
ARC
GLP-1
i3vt
GLP-1
Glucose (mmol/l)
Basal 4.9  0.1 4.6  0.1 4.9  0.2
ICV 4.6  0.1 4.4  0.5 4.9  0.3
Clamp 5.2  0.2 5.4  0.3 5.3  0.2
Insulin (pmol/l)
Basal 67  21 69  16 66  13
ICV 48  10 60  17 52  11
Clamp 285  59 295  48 246  37
Corticosterone (nmol/l)
Basal 13  31 5  31 3  3
ICV 17  31 5  31 3  2
Clamp 13  31 8  21 6  2
Data are means  SE. Neither insulin nor corticosterone levels
signiﬁcantly changed over time in any group during the hyperinsu-
linemic-euglycemic clamp. ICV, intracerebroventricular.
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nor bilateral injection of GLP-1 into the ARC signiﬁ-
cantly affected food intake (Fig. 8). However, as shown
previously (33), unilateral administration of GLP-1 di-
rectly into the PVN signiﬁcantly reduced food intake
(Fig. 8).
DISCUSSION
Many current models hold that peripheral and CNS GLP-1
signaling operate as distinct systems, i.e., CNS GLP-1 to
regulate food intake and circulating GLP-1 to control
glucose homeostasis. Our data challenge this conventional
model by demonstrating that CNS GLP-1 also plays an
important role in regulating glucose tolerance through
coordinate actions on the pancreas and liver.
Although it has long been known that the CNS is vital in
the response to hypoglycemia, there has been less appre-
ciation for the role of the brain to maintain homeostasis
during glucose challenges. However, recent studies using
insulin/glucose clamps have demonstrated that i3vt insulin
administration increased peripheral insulin sensitivity (35)
and inhibited glucose production (36). More speciﬁcally,
restoration of ARC leptin receptors in leptin receptor–
deﬁcient mice improves insulin sensitivity independent
ARC
SAL
ARC
GLP-1
i3vt GLP-1
*
Glucose Uptake
ARC
SAL
ARC
GLP-1
i3vt 
GLP-1
Glucose Infusion Rate 
A
Glucose Production
ARC
SAL
ARC
GLP-1
i3vt GLP-1
B
E
Glucose Production
ARC
SAL
ARC
GLP-1
‡
F
Glucose Uptake
ARC
SAL
ARC
GLP-1
GLP-1+Gli GLP-1+Gli GLP-1+Gli
D
Glucose Infusion Rate 
ARC
SAL
ARC
GLP-1
0
20
40
µ
m
o
l
/
k
g
/
m
i
n
*
*
µ
m
o
l
/
k
g
/
m
i
n
0
40
80
120
µ
m
o
l
/
k
g
/
m
i
n *
0
60
120
µ
m
o
l
/
k
g
/
m
i
n
0
50
100
µ
m
o
l
/
k
g
/
m
i
n
0
50
100
µ
m
o
l
/
k
g
/
m
i
n
0
20
40
C
FIG. 6. Effect of ARC GLP-1 on peripheral glucose homeostasis during a hyperinsulinemic-euglycemic clamp. A: Glucose infusion rate during the
glucose clamp was similar between the three groups. B: Glucose production was signiﬁcantly reduced in ARC GLP-1 versus both saline and i3vt
GLP-1 groups. C: Glucose uptake was signiﬁcantly reduced in ARC and i3vt GLP-1 vs. saline. D: Glucose infusion rate during the hyperinsulinemic-
eulgycemic clamp was similar between saline, ARC GLP-1, and ARC GLP-1 plus glibenclamide. E: Coinfusion of glibenclamide into the ARC
prevented GLP-1–induced inhibition of glucose production. F: Coinfusion of glibenclamide into the ARC prevented GLP-1–induced inhibition of
glucose uptake. *P < 0.05 vs. saline. †P < 0.05 vs. saline and i3vt. ‡P < 0.05 vs. saline and GLP-1 plus glibenclamide.
PVN SAL PVN GLP-1
Glucose Infusion Rate 
A
Endogenous Glucose Production
PVN SAL PVN GLP-1
B
PVN SAL PVN GLP-1
C
Glucose Rate of Disappearance
0
20
40
µ
m
o
l
/
k
g
/
m
i
n
0
50
100
0
50
100
µ
m
o
l
/
k
g
/
m
i
n
µ
m
o
l
/
k
g
/
m
i
n
FIG. 7. Effect of infusion of GLP-1 or saline into the PVN on glucose kinetics. A: Glucose infusion rate during the glucose clamp was similar
between PVN saline and GLP-1 groups. B: Glucose production was similar between the PVN GLP-1 and saline groups. C: Glucose uptake was
similar between the PVN GLP-1 and saline groups.
D.A. SANDOVAL AND ASSOCIATES
DIABETES, VOL. 57, AUGUST 2008 2051of changes in food intake (37,38), and insulin, glucose,
lactate, or long-chain fatty acid administration directly
into the ARC each inhibits glucose production by 30%
more than vehicle during a somatostatin glucose clamp
(26,36,39–41). Importantly, during clamped hyperglyce-
mia/hyperinsulinemia, central GLP-1 signaling promoted
hepatic glucose storage and insulin secretion while
reducing muscle glucose uptake (42), the latter being an
effect that was dependent on neural innervation of the
muscle. These studies establish that CNS centers can
affect key processes involved in glucose metabolism but
do not address regulation of glucose homeostasis be-
cause they used experimental conditions (e.g., glucose
clamps) in the absence of physiological elevations of
glucose.
We chose an alternative approach. In our ﬁrst experi-
ment, we demonstrated that the composite actions initi-
ated by GLP-1 receptor signaling in the brain promote
glucose tolerance. Moreover, because we used a GLP-1
receptor antagonist to elicit this effect, our results indicate
that this is a physiologic action of endogenous GLP-1.
Interestingly, the degree of impairment of glucose toler-
ance with CNS GLP-1 receptor antagonism was compara-
ble with that seen in mice with a whole-body targeted
disruption of the GLP-1 receptor (9). Further, with an
insulin infusion that produces postprandial levels, we
found that ARC GLP-1, compared with saline, inhibited
glucose production by 30% more. Thus, our data extend
previous observations concerning the importance of the
ARC in CNS regulation of glucose levels to include an
important role for GLP-1 signaling and also suggest that
GLP-1 acting speciﬁcally in the ARC, but not in the PVN,
acts similarly to insulin and nutrients to regulate glucose
production (23–25,36,43). Furthermore, our data are sug-
gestive that GLP-1 receptors on POMC or other non-NPY
neurons play an important role in mediating this effect.
Taken together, these ﬁndings suggest that GLP-1 signal-
ing in the brain and the periphery has a role in normal
glucose metabolism.
Little is known regarding GLP-1 signaling in the brain.
In pancreatic 
-cells, glucose inhibits ATP-sensitive K

(KATP) channels, which causes cellular depolarization and
insulin release. Similarly, glucose and insulin reduce KATP
channel currents in lateral ARC neurons (44), and the
effects of CNS administration of insulin (25) and nutrients
(23,24) on glucose production can be abolished by gliben-
clamide, a KATP channel inhibitor. Our data add to this
ﬁnding, as we found that coinfusion of glibenclamide
blocked the effect of GLP-1 on both glucose production
and glucose uptake. Thus, the KATP channels within
the ARC are important for regulating overall glucose
homeostasis.
Using in situ hybridization, we found a subset of ARC
GLP-1 receptor–expressing neurons that are highly colo-
calized with POMC but not NPY neurons and a second
subset that does not coexpress with either NPY or POMC.
Although our data raise the possibility that POMC neurons
within the ARC play a role in mediating the effects of
GLP-1 on glucose homeostasis, the role of the melanocor-
tin system in mediating CNS regulation of glucose ho-
meostasis is not clear. Although 1 week of i3vt
administration of -MSH (-melanocyte–stimulating hor-
mone) has been found to decrease glucose production
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TABLE 4
Effect of ARC, PVN, and i3vt GLP-1 on basal glucose production and uptake
Saline ARC GLP-1 i3vt GLP-1
GLP-1 plus
glibenclamide
Glucose production (mol  kg
1  min
1)
Basal 37  44 2  64 1  43 3  4
ICV infusion 34  33 5  34 0  43 0  3
Glucose uptake (mol  kg
1  min
1)
Basal 35  54 2  63 8  23 3  4
ICV infusion 31  23 5  33 6  23 9  3
Data are means  SE. There were no signiﬁcant effects of intra-ARC or i3vt GLP-1 on glucose production or uptake under basal conditions.
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production. Furthermore, coadministration of a melano-
cortin antagonist failed to block centrally administered
insulin and leptin-induced decreases in glucose production
(40). Such observations point to a potential role for the
GLP-1 receptors that are not localized to either POMC or
NPY neurons in the ARC.
Although glucose excitatory neurons have been identi-
ﬁed in the lateral ARC, controversy arises over their
glucose-sensing properties. For example, in electrophysi-
ological studies, POMC neuronal ﬁring rate decreased with
decreasing levels of glucose (46). However, brain hyper-
glycemia failed to induce Fos or to increase the ﬁring rate
of POMC neurons (47). Our ﬁnding that POMC neurons are
not homogenous and that they are composed of at least
two distinct cell types either coexpressing or lacking
GLP-1 receptors within the ARC might help explain these
discrepancies. Another possibility is that glucose may not
be the primary stimulus for POMC neurons. Instead, GLP-1
either directly, as recently demonstrated in vitro (48), or
indirectly, via release in response to gastric distension
(49), increased blood glucose in the portal system—or, by
neurotransmitter activation in the gastrointestinal tract
(50), might provide stimulation of POMC neurons via
GLP-1 receptors in the ARC.
Despite an overall effect to promote glucose disposition,
ARC GLP-1 inhibited glucose uptake in peripheral tissues.
This seemingly discordant ﬁnding is actually consistent
with previous data that lateral ventricular infusion of a
long-acting GLP-1 analog inhibited skeletal muscle glyco-
gen formation (41). That study suggested that the mecha-
nism was insulin independent and was instead due to
direct neural innervation. An alternative hypothesis is
there is an indirect effect of CNS GLP-1 on glucose uptake.
i3vt administration of GLP-1 increased the proportion of
energy derived from fat over carbohydrate in lean and
obese Zucker rats (51). Increased fat oxidation could
indirectly reduce glucose uptake in muscle (52). Whatever
the mechanism, it is important to note that our data
indicate that with a physiological glucose load, the overall
effect of CNS GLP-1 is to improve glucose homeostasis;
i.e., the pancreatic and hepatic effects override any effect
on skeletal muscle, leading to overall improved glucose
tolerance.
The focus of most studies of the CNS GLP-1 system has
been effects on food intake, and the ability of CNS GLP-1
to cause anorexia is mediated at several cerebral sites,
e.g., lateral (16), 3rd and 4th ventricular (16,53), and PVN
(Fig. 8) (33); in addition, administration of GLP-1 inhibits
food intake. However, only when administered into the 4th
ventricle (16) or PVN (33) does GLP-1 administration
reduce food intake without also causing visceral illness.
This is because GLP-1 receptors in the central nucleus of
the amygdala initiate visceral illness (16), and lateral and
i3vt CNS administration of GLP-1 increases GLP-1 signal-
ing in this nucleus and in brain areas that cause anorexia,
indicating that GLP-1 receptors in speciﬁc nuclei have
discrete effects. Our data extend these ﬁndings by reveal-
ing that GLP-1 receptors within the ARC regulate blood
glucose without affecting food intake while GLP-1 recep-
tors within the PVN regulate food intake without affecting
blood glucose.
Our data indicate a common effect of both peripheral
and central GLP-1 receptor signaling to promote glucose
tolerance, raising the possibility for cross-talk between
circulating GLP-1 and the brain. While our data do not test
this possibility directly, they do indicate that endogenous
CNS GLP-1 receptors are also important mediators of
glucose tolerance. Further, since circulating GLP-1 is not
increased during glucose tolerance tests, peripheral GLP-1
may not be the important source of GLP-1 activating the
CNS receptors that regulate islet and hepatic function.
Long-acting GLP-1 analogs improve glucose homeostasis
in type 2 diabetic patients. The extent to which these
effects are central versus peripheral is unknown, but the
data presented here open up the possibility that some of
the improvement in glucose levels may be the result of
activating ARC GLP-1 receptors.
In conclusion, our data illustrate a novel role for CNS
GLP-1 signaling, speciﬁcally on ARC neurons, to regu-
late glucose homeostasis but not food intake. We hy-
pothesize that, after a meal, the coordinated effects of
the CNS GLP-1 system are to stimulate the pancreas to
secrete insulin and inhibit glucose production but also
to inhibit glucose uptake in a KATP channel–dependent
manner. Thus, the CNS makes a number of key contri-
butions to the overall effects of GLP-1 to limit postpran-
dial glucose ﬂuctuations.
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